BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Top notch DSLR Cameras for Photography Devotees- Nuno Loureiro, MIT physicist, fatally shot at home; police investigate
- Best bar-b-que Style: Which One Is Your Number one?
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- The 10 Most Compelling Forerunners in Innovation
- Shooting of MIT professor Nuno Loureiro has police searching for a suspect
- Watch South Korean startup Innospace attempt its 1st-ever orbital launch today
- December's overlooked meteor shower peaks next week — will the Ursids surprise us?
- NASA's SPHEREx telescope completes its 1st cosmic map of the entire sky and it's stunning!
